Kiladjianm, J., Marin, F. F., Al-Ali, H. K., Alvarez-Larrán, A., Beggiato, E., Bieniaszewska, M., . . . Reiter, A. (2024). ROP-ET: A prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Annals of hematology, 103(7), . https://doi.org/10.1007/s00277-024-05665-4
Chicago-Zitierstil (17. Ausg.)Kiladjianm, Jean-Jacques, et al. "ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options." Annals of Hematology 103, no. 7 (2024). https://doi.org/10.1007/s00277-024-05665-4.
MLA-Zitierstil (9. Ausg.)Kiladjianm, Jean-Jacques, et al. "ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options." Annals of Hematology, vol. 103, no. 7, 2024, https://doi.org/10.1007/s00277-024-05665-4.